Ranbaxy Loses Its Exclusivity For Stomach Treatment Drug
Advertisement
Advertisement
Advertisement
In a letter to the National Stock Exchange (“We have now received a communication from the USFDA that they have determined that Ranbaxy has forfeited its 180 day exclusivity for esomeprazole magnesium delayed release capsule 20 mg and 40 mg,” the company said in its disclosure to the exchange.
It further added, “On November 4, 2014, we received a notice from the USFDA rescinding our tentative approvals for Esomeprazole magnesium delayed release capsule 20 mg and 40 mg and for valganciclovir hydrochloride tablets USP, 450mg.”
The company has expressed its disappointment over the latest development and is considering legal recourse to preserve its rights on the drugs.
Representational Image
Advertisement
- I spent 2 weeks in India. A highlight was visiting a small mountain town so beautiful it didn't seem real.
- I quit McKinsey after 1.5 years. I was making over $200k but my mental health was shattered.
- Some Tesla factory workers realized they were laid off when security scanned their badges and sent them back on shuttles, sources say
- Stock markets stage strong rebound after 4 days of slump; Sensex rallies 599 pts
- Sustainable Transportation Alternatives
- 10 Foods you should avoid eating when in stress
- 8 Lesser-known places to visit near Nainital
- World Liver Day 2024: 10 Foods that are necessary for a healthy liver